Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829919 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
A Phase 1 study of Postmenopausal Symptoms, sponsored by Noven Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01829919 is a Phase 1 study of Postmenopausal Symptoms that has completed, run by Noven Therapeutics. The registered enrollment target is 24 participants, below the 94-participant average among 7 other Postmenopausal Symptoms trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01829919, a Phase 1 study of Postmenopausal Symptoms, has completed, sponsored by Noven Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and multiple doses.
Conditions Studied
Interventions
- DRUG Brisdelle (paroxetine mesylate)
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829919
The ClinicalTrials.gov registry entry for NCT01829919 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 7 other Postmenopausal Symptoms trials with a reported enrollment target (74% lower). The listed sponsor is Noven Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postmenopausal Symptoms appearing as the primary indexed condition, and to 1 intervention - of which Brisdelle (paroxetine mesylate) is the first listed.
NCT01829919 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01829919 about?
NCT01829919 is a clinical study titled "Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women". The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and multiple doses.
What is the current status of trial NCT01829919?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-07. Estimated completion is 2011-08.
What conditions does trial NCT01829919 study?
This clinical trial studies the following conditions: Postmenopausal Symptoms.
What interventions are being tested in trial NCT01829919?
The interventions under investigation include: Brisdelle (paroxetine mesylate) (DRUG).
Who is sponsoring clinical trial NCT01829919?
This trial is sponsored by Noven Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01829919 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise Training and Fat Metabolism in Postmenopausal Women
RECRUITING · NA
-
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
RECRUITING · NA
-
PRP Injections for Genitourinary Syndrome of Menopause
ACTIVE NOT RECRUITING · NA
-
Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy
COMPLETED · Phase 4
-
Inspiratory Muscle Training in Postmenopausal Women
COMPLETED · NA
-
Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.